Candel Therapeutics Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Candel Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2836 — Biological Products, (No Diagnostic Substances)
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Needham
- Headquarters state / province
- Massachusetts
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- CADL
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001841387
- EIN
- 52-2214851
Board of directors
-
Christopher Martell · DirectorSince 2023
-
Diem Nguyen · DirectorSince 2023
-
Edward J. Benz Jr. · DirectorSince 2023
-
Estuardo Aguilar-Cordova · DirectorSince 2023
-
Gary J. Nabel · DirectorSince 2023
-
Joseph C. Papa · DirectorSince 2023
-
Maha Radhakrishnan · DirectorSince 2025
-
Martine Zimmermann · DirectorSince 2026
-
Nicoletta Loggia · DirectorSince 2023
-
Paul B. Manning · DirectorSince 2023
-
Paul Peter Tak · Director · Chief Executive OfficerSince 2023
-
Renee Gaeta · DirectorSince 2023
Chief executives
Paul Peter Tak
· Chief Executive Officer
Dates unknown
Director election results
Annual meeting of June 23, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
78.6%
-
98.0%
-
99.7%
Board connections
6 of this board's directors also sit on 9 other boards.
- via Diem Nguyen and Gary J. Nabel
- via Diem Nguyen and Paul B. Manning
- via Maha Radhakrishnan
- via Joseph C. Papa
- via Maha Radhakrishnan
- via Martine Zimmermann
- via Paul B. Manning
- via Joseph C. Papa
- via Gary J. Nabel
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $2,999,996
- 1 purchase by 1 insider
- Sold, last 12 months
- $3,550,703
- 5 sales by 3 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 11, 2026 | Paul Peter Tak Director, Officer (Chief Executive Officer) | Open-market sale | −59,379 | $10.46 | $620,891 |
| Sep 10, 2026 | Paul Peter Tak Director, Officer (Chief Executive Officer) | Option exercise | +125,000 | $1.55 | $193,750 |
| Sep 10, 2026 | Paul Peter Tak Director, Officer (Chief Executive Officer) | Open-market sale | −220,866 | $11.50 | $2,539,893 |
| Aug 17, 2026 | Tyagarajan Seshu Officer (Chief Technology Officer) | Open-market sale | −7,000 | $12.00 | $84,000 |
| Jun 29, 2026 | Barone Francesca Officer (Chief Scientific Officer) | Open-market sale | −23,447 | $10.06 | $235,769 |
| Jun 29, 2026 | Tyagarajan Seshu Officer (Chief Technology Officer) | Open-market sale | −7,000 | $10.02 | $70,151 |
| Feb 23, 2026 | Paul B. Manning Director | Open-market purchase | +550,458 | $5.45 | $2,999,996 |
| Jul 28, 2025 | Nichols William Garrett Officer (Chief Medical Officer) | Option exercise | +937 | $1.29 | $1,209 |
| Jul 28, 2025 | Nichols William Garrett Officer (Chief Medical Officer) | Open-market sale | −937 | $6.98 | $6,540 |
| Jun 30, 2025 | Nichols William Garrett Officer (Chief Medical Officer) | Option exercise | +781 | $1.29 | $1,007 |
| Jun 30, 2025 | Nichols William Garrett Officer (Chief Medical Officer) | Open-market sale | −781 | $5.04 | $3,936 |
| Jun 25, 2025 | Tyagarajan Seshu Officer (Chief Technology Officer) | Grant or award | +5,353 | $4.67 | $24,999 |
| Jun 25, 2025 | Paul Peter Tak Director, Officer (Chief Executive Officer) | Grant or award | +42,826 | $4.67 | $199,997 |
| Jun 25, 2025 | Paul B. Manning Director | Grant or award | +1,070,663 | $4.67 | $4,999,996 |
| Jun 25, 2025 | Christopher Martell Director | Grant or award | +111,349 | $4.67 | $520,000 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.